Milano M, Guerin O
Centre Hospitalier Universitaire de Nice, Hôpital de Tende - Service Pharmacie, Tende, France.
J Oncol Pharm Pract. 2006 Jun;12(2):69-73. doi: 10.1177/1078155206070414.
Recent advances in the molecular biology and genetics of colorectal cancer have led to the identification of potential therapeutic targets such as epidermal growth factor receptor, vascular endothelial growth factor and endothelial receptors.
This review will examine the major therapeutic advances along with the preclinical basis justifying their combination with conventional therapeutic tools. This review will also critically consider current possibilities offered to identify responding patients.
Preclinical and primary clinical trial results published in peer-review journals. The authors examined the relevance and subsequent inclusion of the data.
Cetuximab and bevacizumab provide new benefits in terms of the response rate and survival. There remain, however, important questions concerning, for instance, optimal combinations between conventional cytotoxic agents and targeted therapies and also between targeted drugs themselves. These new targeted treatments are costly and in this context the question of the identification of the right drug for the right patient is particularly relevant. Adequate tools in predicting the efficacy of targeted treatments are still needed.
结直肠癌分子生物学和遗传学的最新进展已促使人们识别出潜在的治疗靶点，如表皮生长因子受体、血管内皮生长因子和内皮受体。
本综述将探讨主要的治疗进展以及证明其与传统治疗手段联合使用合理性的临床前依据。本综述还将批判性地考虑目前用于识别有反应患者的可能性。
发表于同行评审期刊的临床前和主要临床试验结果。作者检查了数据的相关性及后续纳入情况。
西妥昔单抗和贝伐单抗在缓解率和生存率方面带来了新的益处。然而，仍存在一些重要问题，例如传统细胞毒性药物与靶向治疗之间以及靶向药物本身之间的最佳联合方式。这些新的靶向治疗费用高昂，在这种情况下，为合适的患者选择合适药物的问题尤为重要。仍需要足够的工具来预测靶向治疗的疗效。
